Dr. Cornelius Clancy, MD

NPI: 1326075094
Total Payments
$166,876
2024 Payments
$12,895
Companies
10
Transactions
116

Payment Breakdown by Category

Consulting$58,672 (35.2%)
Travel$55,043 (33.0%)
Other$50,969 (30.5%)
Food & Beverage$1,772 (1.1%)
Education$420.00 (0.3%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $58,672 21 35.2%
Travel and Lodging $55,043 42 33.0%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47,519 10 28.5%
Compensation for serving as faculty or as a speaker for a medical education program $2,700 1 1.6%
Food and Beverage $1,772 40 1.1%
Honoraria $750.00 1 0.4%
Education $420.00 1 0.3%

Top Paying Companies

Company Total Records Latest Year
Merck Sharp & Dohme LLC $91,617 60 $0 (2022)
Shionogi Inc $43,080 40 $0 (2024)
Astellas Pharma Inc $24,911 5 $0 (2017)
Gilead Sciences, Inc. $3,230 1 $0 (2024)
La Jolla Pharmaceutical Company $2,882 2 $0 (2023)
Meitheal Pharmaceuticals, Inc. $830.19 2 $0 (2024)
The Medicines Company $117.59 2 $0 (2017)
SCYNEXIS, Inc. $92.87 2 $0 (2022)
Melinta Therapeutics, Inc. $88.02 1 $0 (2018)
GlaxoSmithKline, LLC. $27.78 1 $0 (2023)

Payment History by Year

Year Amount Transactions Top Company
2024 $12,895 5 Shionogi Inc ($8,835)
2023 $5,609 4 La Jolla Pharmaceutical Company ($2,882)
2022 $19,416 19 Merck Sharp & Dohme LLC ($17,973)
2021 $6,105 3 Shionogi Inc ($3,900)
2020 $7,250 3 Merck Sharp & Dohme Corporation ($5,950)
2019 $39,174 29 Merck Sharp & Dohme Corporation ($27,380)
2018 $36,068 40 Merck Sharp & Dohme Corporation ($23,183)
2017 $40,359 13 Astellas Pharma Inc ($24,911)

All Payment Transactions

116 individual payment records from CMS Open Payments — Page 1 of 5

Date Company Product Nature Form Amount Type
11/14/2024 Meitheal Pharmaceuticals, Inc. Honoraria Cash or cash equivalent $750.00 General
10/18/2024 Meitheal Pharmaceuticals, Inc. Food and Beverage In-kind items and services $80.19 General
10/15/2024 Shionogi Inc Fetroja (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program In-kind items and services $8,818.08 General
Category: Infections and Infectious Diseases
04/25/2024 Shionogi Inc Fetroja (Drug) Food and Beverage In-kind items and services $16.80 General
Category: Infections and Infectious Diseases
02/29/2024 Gilead Sciences, Inc. AmBisome (Drug) Consulting Fee Cash or cash equivalent $3,230.00 General
Category: OTHER
10/14/2023 GlaxoSmithKline, LLC. Food and Beverage In-kind items and services $27.78 General
10/11/2023 La Jolla Pharmaceutical Company XACDURO (Drug) Consulting Fee Cash or cash equivalent $2,680.00 General
Category: INFECTIOUS DISEASE
10/11/2023 La Jolla Pharmaceutical Company XACDURO (Drug) Consulting Fee In-kind items and services $201.51 General
Category: INFECTIOUS DISEASE
01/13/2023 Shionogi Inc Fetroja (Drug) Compensation for serving as faculty or as a speaker for a medical education program Cash or cash equivalent $2,700.00 General
Category: Infections and Infectious Diseases
10/19/2022 SCYNEXIS, Inc. Food and Beverage In-kind items and services $76.11 General
10/19/2022 SCYNEXIS, Inc. Food and Beverage In-kind items and services $16.76 General
07/21/2022 Shionogi Inc Fetroja (Drug) Consulting Fee Cash or cash equivalent $1,350.00 General
Category: Infections and Infectious Diseases
05/02/2022 Merck Sharp & Dohme LLC Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $5,580.00 General
05/02/2022 Merck Sharp & Dohme LLC Travel and Lodging Cash or cash equivalent $150.00 General
04/27/2022 Merck Sharp & Dohme LLC Consulting Fee Cash or cash equivalent $930.00 General
04/24/2022 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $6,914.07 General
Category: INFECTIOUS DISEASE
04/24/2022 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program In-kind items and services $421.31 General
Category: INFECTIOUS DISEASE
04/24/2022 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $157.41 General
Category: INFECTIOUS DISEASE
04/24/2022 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $66.51 General
Category: INFECTIOUS DISEASE
04/24/2022 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Food and Beverage In-kind items and services $24.38 General
Category: INFECTIOUS DISEASE
04/24/2022 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $19.40 General
Category: INFECTIOUS DISEASE
04/23/2022 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $157.41 General
Category: INFECTIOUS DISEASE
04/23/2022 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Food and Beverage In-kind items and services $55.42 General
Category: INFECTIOUS DISEASE
04/23/2022 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Food and Beverage In-kind items and services $12.19 General
Category: INFECTIOUS DISEASE
04/22/2022 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $157.41 General
Category: INFECTIOUS DISEASE

About Dr. Cornelius Clancy, MD

Dr. Cornelius Clancy, MD is a Infectious Disease healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326075094.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cornelius Clancy, MD has received a total of $166,876 in payments from pharmaceutical and medical device companies, with $12,895 received in 2024. These payments were reported across 116 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($58,672).

Practice Information

  • Specialty Infectious Disease
  • Location Gainesville, FL
  • Active Since 06/27/2006
  • Last Updated 02/14/2008
  • Taxonomy Code 207RI0200X
  • Entity Type Individual
  • NPI Number 1326075094

Products in Payments

  • Fetroja (Drug) $29,878
  • Micafungin (Drug) $24,911
  • ZERBAXA (Drug) $15,467
  • AmBisome (Drug) $3,230
  • XACDURO (Drug) $2,882
  • VABOMERE (Drug) $117.59

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Infectious Disease Doctors in Gainesville